STVN vs UBS: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
UBS is the larger of the two ($132.60B market cap): the incumbent the market prices for continued execution (10.16x forward earnings, beta 0.84). STVN is the smaller challenger ($4.30B), actually pricier on forward earnings (21.73x): more room to run, but more to prove. If you believe STVN earns its premium (21.73x forward earnings, so the market expects more from it), STVN fits. If you believe in paying less for profit, UBS fits at 10.16x.
STVN vs UBS: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | STVN | UBS | What it tells you |
|---|---|---|---|
| Market cap | $4.30B | $132.60B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 21.73 | 10.16 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 26.66 | 14.44 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.80 | 0.84 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 31% of range | 38% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.40 | 1.50 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: UBS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how STVN and UBS affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. STVN and UBS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined STVN and UBS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Stevanato Group S.p.A. (STVN) do?
Stevanato Group has been making pharmaceutical glass in Piombino Dese, near Padua in northern Italy, since 1949, and sells its containers under the Ompi brand. The business runs in two segments. Biopharmaceutical and Diagnostic Solutions covers vials, syringes, cartridges, EZ-fill ready-to-use containers and the Alina pen injector platform, and produced ~EUR 294 million of the ~EUR 326.1 million total in the third quarter of 2026. Engineering builds the assembly, visual inspection and glass converting machinery that drug makers and other packaging firms use on their own lines, and contributed the remaining ~EUR 32 million. The company listed ordinary shares on the New York Stock Exchange in July 2021, but it remains an Italian issuer that reports in euros and files as a foreign private issuer, and the founding family retains roughly four fifths of the shares through Stevanato Holding S.r.l., with Italian loyalty-share rules adding extra votes on top of that.
What does UBS Group (UBS) do?
UBS Group is a Swiss-headquartered global financial-services firm built around wealth management. Its Global Wealth Management arm advising high-net-worth and ultra-high-net-worth clients is the largest such franchise in the world, and it is complemented by an asset-management business, a leading Swiss universal bank serving domestic retail and corporate clients, and an investment bank focused on advisory, markets, and financing. Because much of its revenue is fee-based, tied to client assets and advice rather than pure lending, UBS is often viewed as a higher-quality, less credit-cyclical bank than many peers, though its investment bank and lending books still carry market and credit exposure.
STVN vs UBS: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- STVN drivers: The high-value solutions mix shift; Injectable biologics volumes, GLP-1 included.
- UBS drivers: World-leading wealth management; Credit Suisse integration and synergies.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Customer concentration and destocking have hit this company before and did again in November 2026: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and after the third-quarter 2026 report flagged lower 2027 GLP-1 volumes from one customer the stock dropped ~19% over the following month. For UBS, the dominant near-term risk is integration execution: absorbing Credit Suisse is a large, multi-year effort, and client attrition, technology migration, legal legacy issues, or cost overruns could reduce the expected synergies.
STVN or UBS: which should you pick?
If the story you believe is STVN's (The high-value solutions mix shift), STVN is the more direct way to own it; if it is UBS's (World-leading wealth management), UBS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the STVN and UBS guides.
STVN vs UBS: the full fundamentals
STVN. Every operating figure above is reported in euros because Stevanato is an Italian issuer, while the share price and market capitalization are quoted in US dollars on the NYSE, so the two sets of numbers move on different currencies and should not be compared directly. The trailing multiple has come down from ~33 times in October to ~27 times as of November 20, 2026, as the shares fell ~19% in a month on the 2027 GLP-1 warning, and consensus now looks for 2027 EPS of ~0.72 on ~EUR 1.3 billion of revenue, about ~6% growth. The analyst mean target was ~$19.46 across 12 analysts, with a Buy consensus despite the William Blair downgrade.
UBS. These figures are approximate and tied to the asOf date; verify live numbers before acting. At about 14.5 times trailing and 10 times forward earnings and 1.5 times book, UBS is priced more cheaply than in October, after the shares slipped about 19% over three months as the Swiss capital debate dragged on. Consensus has 2026 EPS near $3.79 and 2027 near $4.31, with about $0.99 expected for the December quarter, so the final capital rules remain the main open question for how much of that profit reaches shareholders.
Headline figures (approximate, November 2026): STVN shows revenue (ttm) ~EUR 1.25 billion, Q3 2026 up ~8% year over year, q3 2026 revenue ~EUR 326.1 million, adjusted diluted EPS ~EUR 0.16 (Yahoo basis 0.18 vs 0.18 est.), margins (ttm) gross ~29%, operating ~18%, net ~11%, net income (ttm) ~EUR 140 million; UBS shows revenue (ttm) ~$54.6 billion; Q3 2026 ~$11.1 billion, up ~12% YoY, net income (ttm) ~$9.7 billion; Q3 2026 ~$2.2 billion, latest eps vs estimate Q3 2026 $0.96 vs $0.96 expected; Q2 2026 $0.93 vs $0.98, profit margin ~18% (TTM); operating margin ~32%.
The bottom line: STVN vs UBS
STVN and UBS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined STVN and UBS exposure against your real portfolio. It is not an investment adviser.
Wondering how STVN or UBS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Stevanato Group S.p.A.
Ask Walnut's AI anything about STVN and see how it fits what you own.
FAQ
What is the difference between STVN and UBS?
+
Stevanato Group has been making pharmaceutical glass in Piombino Dese, near Padua in northern Italy, since 1949, and sells its containers under the Ompi brand. UBS Group is a Swiss-headquartered global financial-services firm built around wealth management. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is STVN or UBS the better stock?
+
Neither is universally better. UBS is the larger incumbent; STVN is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, STVN or UBS?
+
On forward P/E (as of November 2026), STVN trades at 21.73x and UBS at 10.16x, so UBS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both STVN and UBS?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of STVN vs UBS?
+
STVN: Customer concentration and destocking have hit this company before and did again in November 2026: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and after the third-quarter 2026 report flagged lower 2027 GLP-1 volumes from one customer the stock dropped ~19% over the following month. Plaintiff firms opened investigations after both episodes, the latest focused on the company's GLP-1 disclosure; those are investigations, not filed litigation, as far as the public record shows. Capital intensity remains the near-term drag, with full-year 2026 capital expenditure guided to ~EUR 230 million to ~EUR 240 million gross, trailing free cash flow of ~negative $65 million on Yahoo's basis and net debt of ~EUR 353.7 million at the end of September. GLP-1 exposure now reads as ~17% to ~18% of revenue, still a single point of failure if pricing, supply or dosing formats change, and the 2026 launch of oral GLP-1 pills turned the dosing-format risk from hypothetical to live. Governance leaves outside holders with limited influence, because family control through Stevanato Holding S.r.l. plus enhanced voting rights means minority shareholders cannot force a change of direction. Finally, the reporting currency is the euro while the quote is in dollars, so a US holder absorbs the exchange rate on top of the operating result, and at roughly ~27 times trailing and ~22 times forward earnings as of November 2026 the price still assumes the mix shift and the new plants deliver once the 2027 slowdown passes. UBS: The dominant near-term risk is integration execution: absorbing Credit Suisse is a large, multi-year effort, and client attrition, technology migration, legal legacy issues, or cost overruns could reduce the expected synergies. Regulatory and capital risk is significant, as Swiss authorities have pushed to raise capital requirements for UBS given its size relative to Switzerland (a proposal that could tie up more than $20 billion), which could constrain dividends and buybacks. Contingency talk of a headquarters move or merger, reported in October 2026, adds a further layer of uncertainty in either direction. As a global bank, UBS is exposed to market downturns that reduce client assets and fee income, to investment-bank volatility, and to credit and counterparty risk. It is also a Swiss company whose US-listed shares carry currency exposure between the Swiss franc, the euro, the dollar, and other currencies. Legal and litigation legacies inherited from Credit Suisse add further uncertainty. The shares fell about 19% over the three months to November 20, 2026 as the capital debate continued, a reminder that the stock trades heavily on regulatory headlines.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell STVN or UBS; figures are approximate and dated (as of November 2026). Verify current data before investing.